|
CAR-T Cell Therapy Clinical Trials
10 actively recruiting trials across 2 locations
▲ +2 trials since May 2026
Also known as: Axicabtagene ciloleucel, Chimeric Antigen Receptor T-cell, Chimeric antigen receptor T-Cell Therapy, Lisocabtagene maraleucel .
Pipeline
Phase 1: 4Phase 2: 4Phase 1/2: 1
Top Sponsors
- The First Affiliated Hospital of Soochow University3
- National University Hospital, Singapore2
- Washington University School of Medicine1
- University Hospital, Lille1
- Lazaros Lekakis1
Indications
- Cancer10
- CAR T-Cell-Related Encephalopathy Syndrome2
- Lymphoblastic Leukemia, Acute, Childhood2
- CAR2
- Lymphoblastic Leukemia, Acute Adult2
Other8 trials
Miami, Florida1 trial
St Louis, Missouri1 trial
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Washington University School of Medicine
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.